Alto Neuroscience, Inc. Cash Flow-to-Debt Ratio
Alto Neuroscience, Inc. cash flow-to-debt ratio. Alto Neuroscience, Inc. (ANRO) has a Cash Flow-to-Debt Ratio of -0.34x as of December 2025, meaning its operating cash flow of $-11.52 Million could theoretically repay 0% of its total liabilities ($33.55 Million) in one year. See Alto Neuroscience, Inc. (ANRO) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Alto Neuroscience, Inc. (2021–2025)
Cash flow-to-debt ratio of Alto Neuroscience, Inc. from 2021 to 2025. Historical debt coverage capacity for Alto Neuroscience, Inc. across 5 annual periods. Also explore how fast is Alto Neuroscience, Inc. growing its equity to track the company's year-over-year net asset growth rate.
Alto Neuroscience, Inc. Cash Flow-to-Debt Ratio by Year (2021–2025)
Alto Neuroscience, Inc. cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for Alto Neuroscience, Inc.. For the full cash flow conversion analysis, see Alto Neuroscience, Inc. cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.54x | $-51.77 Million | $33.55 Million | ▲ +15.1% |
| 2024 | -1.82x | $-47.42 Million | $26.08 Million | ▼ -760.5% |
| 2023 | -0.21x | $-33.45 Million | $158.30 Million | ▲ +7.5% |
| 2022 | -0.23x | $-20.39 Million | $89.26 Million | ▼ -1.8% |
| 2021 | -0.22x | $-9.26 Million | $41.27 Million | — |